Apealea® (paclitaxel micellar)
Apealea® (paclitaxel micellar)
In December 2020 Inceptua licensed the global commercial rights of Apealea from Elevar Therapeutics Inc.
Apealea (paclitaxel micellar) is a prescription medicine, indicated for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer, in combination with carboplatin.
Apealea is a cremophor-free paclitaxel that does not contain polyoxyl caster oil or ethanol and does not require mandatory pre-medication.
Please always consult local prescribing information and labelling text before use.
For more information about Apealea please refer to the prescribing information: European Medicines Agency
Privacy notice
Health Care Professionals and Adverse Event Report Privacy Notice.
Medical Information
If you would like to speak to a medical representative, please contact:
inceptua.mi@primevigilance.com
+49 30 1202 1381
Safety and adverse events
Patient safety is a key priority for us. For any suspected adverse drug reactions associated with Apealea, please contact:
+49 30 1202 1381
Inceptua Pharma Medicines Access Policy